Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
http://dx.doi.org/10.25673/102270
Langanzeige der Metadaten
DC Element | Wert | Sprache |
---|---|---|
dc.contributor.author | Liu, Qiaofei | - |
dc.contributor.author | Li, Jiayi | - |
dc.contributor.author | Zheng, Huaijin | - |
dc.contributor.author | Yang, Sen | - |
dc.contributor.author | Hua, Yuze | - |
dc.contributor.author | Huang, Nan | - |
dc.contributor.author | Kleeff, Jörg H. | - |
dc.contributor.author | Liao, Quan | - |
dc.contributor.author | Wu, Wenming | - |
dc.date.accessioned | 2023-04-19T12:09:29Z | - |
dc.date.available | 2023-04-19T12:09:29Z | - |
dc.date.issued | 2023 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/104223 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/102270 | - |
dc.description.abstract | In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration of new immunotherapeutic modalities. The failure of CAR-T and immune checkpoint blockade in several solid neoplasms is attributed to multiple factors, including low antigenicity of tumor cells, low infiltration of effector T cells, and diverse mechanisms of immunosuppression in the tumor microenvironment. New adoptive cell therapies have been attempted for solid neoplasms, including TCR-T, CAR-natural killer cells (CAR-NK), and CAR-macrophages (CAR-M). Compared to CAR-T, these new adoptive cell therapies have certain advantages in treating solid neoplasms. In this review, we summarized the 40-year evolution of adoptive cell therapies, then focused on the advances of TCR-T, CAR-NK, and CAR-M in solid neoplasms and discussed their potential clinical applications. | eng |
dc.language.iso | eng | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject.ddc | 610 | - |
dc.title | Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T | eng |
dc.type | Article | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | Molecular cancer | - |
local.bibliographicCitation.volume | 22 | - |
local.bibliographicCitation.publishername | Biomed Central | - |
local.bibliographicCitation.publisherplace | London | - |
local.bibliographicCitation.doi | 10.1186/s12943-023-01735-9 | - |
local.subject.keywords | Adoptive cell therapy, Immune checkpoint, Chimeric antigen receptor, TCR , Natural killer cell, Macrophage | - |
local.openaccess | true | - |
dc.identifier.ppn | 1843156644 | - |
local.bibliographicCitation.year | 2023 | - |
cbs.sru.importDate | 2023-04-19T12:09:03Z | - |
local.bibliographicCitation | Enthalten in Molecular cancer - London : Biomed Central, 2002 | - |
local.accessrights.dnb | free | - |
Enthalten in den Sammlungen: | Open Access Publikationen der MLU |
Dateien zu dieser Ressource:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
s12943-023-01735-9.pdf | 4.29 MB | Adobe PDF | ![]() Öffnen/Anzeigen |